United Therapeutics (NASDAQ:UTHR) is set to report earnings this Wednesday. Last quarter, the company missed revenue expectations, reporting revenues of $799.5 million, up 6.8% year on year. Analysts expect revenue to grow 10.1% this quarter. Peers like Biogen and Halozyme Therapeutics have already reported their Q4 results, with Biogen beating revenue expectations by 3.6% and Halozyme Therapeutics reporting a 51.6% revenue increase. The outlook for 2025 remains uncertain due to potential trade policy changes and corporate tax discussions. United Therapeutics stock is currently priced at $476.63 with an average analyst price target of $538.58.

Read more at StockStory: United Therapeutics (UTHR) Q4 Earnings Report Preview: What To Look For